Evaluation of salmon calcitonin treatment in bone metastases from breast cancer--a controlled trial.
Salmon calcitonin 100 MRCU/day or a saline placebo were given in daily injections for at least three months to 49 patients with bone metastases from breast cancer in a randomized double-blind trial. All patients were normocalcemic, and most patients had stable or regressing disease at start of trial. No improvement in general performance or bone pain was detected as measured by a visual analogue scale, the daily duration of pain or consumption of analgetic drugs. Calcitonin had no effect on disease progression as judged by bone scans and radiographs. Calcitonin therapy did not affect serum calcium, alkaline phosphatase, bone gla-protein, or the urinary excretion of calcium and hydroxyproline. Serum phosphate and magnesium decreased significantly during calcitonin treatment (p = 0.01, and 0.00005, respectively). It was concluded that salmon calcitonin in this dosage has no discernible effect on skeletal pain, general performance, bone metabolism or disease progression in patients with breast cancer metastatic to bone. A significant decrease in serum phosphate and magnesium probably indicated an effect of calcitonin on the renal excretion of these ions.
Blomqvist
C
C
Department of Radiotherapy and Oncology, Helsinki University Central Hospital, Finland.
Elomaa
I
I
Porkka
L
L
Karonen
S L
SL
Lamberg-Allardt
C
C
D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D001943:Breast Neoplasms; D002116:Calcitonin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004573:Electrolytes / Q000097:blood; D005260:Female; D006801:Humans; D010146:Pain; D011897:Random Allocation
D004573:Electrolytes; C028815:salmon calcitonin; D002116:Calcitonin